ARVINAS, INC.ARVNEarnings & Financial Report
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, including PROTAC molecules, to treat cancer and rare diseases. It operates primarily in the U.S. and global biopharma markets, advancing multiple pipeline candidates through clinical trials to address unmet medical needs.
ARVN Q3 FY2025 Key Financial Metrics
Revenue
$41.9M
Gross Profit
N/A
Operating Profit
$-43.8M
Net Profit
$-35.1M
Gross Margin
N/A
Operating Margin
-104.5%
Net Margin
-83.8%
YoY Growth
-59.1%
EPS
$-0.48
ARVINAS, INC. Q3 FY2025 Financial Summary
ARVINAS, INC. reported revenue of $41.9M (down 59.1% YoY) for Q3 FY2025, with a net profit of $-35.1M (up 28.7% YoY) (-83.8% margin).
Key Financial Metrics
| Total Revenue | $41.9M |
|---|---|
| Net Profit | $-35.1M |
| Gross Margin | N/A |
| Operating Margin | -104.5% |
| Report Period | Q3 FY2025 |
ARVINAS, INC. Annual Revenue by Year
ARVINAS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $263.4M).
ARVINAS, INC. Quarterly Revenue & Net Profit History
ARVINAS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $41.9M | -59.1% | $-35.1M | -83.8% |
| Q1 FY2025 | $188.8M | +646.2% | $82.9M | 43.9% |
| Q4 FY2024 | $59.2M | +237.4% | $-45.1M | -76.2% |
| Q3 FY2024 | $102.4M | +196.0% | $-49.2M | -48.0% |
| Q2 FY2024 | $76.5M | +40.4% | $-35.2M | -46.0% |
| Q1 FY2024 | $25.3M | -22.2% | $-69.4M | -274.3% |
| Q4 FY2023 | $-43.1M | -213.7% | $-154.8M | 359.2% |
| Q3 FY2023 | $34.6M | +4.2% | $-64.0M | -185.0% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.6M | $-43.1M | $25.3M | $76.5M | $102.4M | $59.2M | $188.8M | $41.9M |
| YoY Growth | 4.2% | -213.7% | -22.2% | 40.4% | 196.0% | 237.4% | 646.2% | -59.1% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.06B | $1.30B | $1.21B | $1.28B | $1.17B | $1.09B | $1.00B | $844.3M |
| Liabilities | $601.1M | $644.6M | $602.9M | $679.4M | $581.1M | $529.7M | $341.0M | $279.9M |
| Equity | $457.2M | $660.0M | $609.7M | $600.2M | $586.0M | $561.7M | $660.1M | $564.4M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-84.8M | $-83.1M | $-97.5M | $50.3M | $-128.0M | $-84.1M | $-88.9M | $-59.1M |